Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery

The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography

This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events

Inclusion Criteria:

• Ability to sign informed consent
• Elective cardiac surgery patients undergoing primary surgery involving circulatory arrest

Exclusion Criteria:

• Inability to sign informed consent
• Baseline hypercoagulable condition as defined in medical record
• Coronary disease with untreated lesions or recent coronary stent placement
• Severe renal dysfunction (ESRD) as documented in medical record